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Abstract
To combine the potency of trimetrexate (TMQ) or piritrexim (PTX) with the species selectivity of 
trimethoprim (TMP), target based design was carried out with the X-ray crystal structure of human 
dihydrofolate reductase (hDHFR) and the homology model of Pneumocystis jirovecii DHFR 
(pjDHFR). Using variation of amino acids such as Met33/Phe31 (in pjDHFR/hDHFR) that affect 
the binding of inhibitors due to their distinct positive or negative steric effect at the active binding 
site of the inhibitor, we designed a series of substituted-pyrrolo[2,3-d]pyrimidines. The best 
analogs displayed better potency (IC50) than PTX and high selectivity for pjDHFR versus hDHFR, 
with 4 exhibiting a selectivity for pjDHFR of 24-fold.
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1. Introduction
Pneumocystis jirovecii (pj) is a fungus that infects the lungs of a majority of humans around 
the world. However, the immune system in healthy individuals keeps the infection under 
control. In immunocompromised patients, pj infection causes Pneumocystis pneumonia 
(PCP).1, 2 PCP can be fatal for patients with HIV/AIDS (most common), patients 
undergoing chemotherapy for cancer, patients on immunosuppressive medications, patients 
undergoing organ or bone-marrow transplantation or those who are malnourished.3, 4 PCP 
presents itself when the patients’ CD4 count is below 200 cells/mm3.5 Although PCP 
prophylaxis and antiretroviral therapy (ART) have changed the face of the HIV/AIDS 
epidemic, the incidence of HIV cases persist due to non-adherence to the medication, 
toxicity to the medications, emergence of drug resistant HIV strains, late diagnosis of HIV 
and the rise in the number of cases in developing countries.6, 7 Thus PCP continues to be a 
significant public health concern. In the US, 9% of the hospitalized HIV/AIDS and 1% of 
organ transplant patients develop PCP infection.8 In these patients, the mortality rate is from 
5–40% while being treated for PCP and approaches 100% if left untreated.8
Both the prophylaxis and treatment for PCP involves the combination of trimethoprim 
(TMP)-sulfamethoxazole (SMX) (co-trimoxazole).9, 10 TMP (Figure 1) is a selective, but 
weak inhibitor of dihydrofolate reductase (DHFR), the enzyme necessary for the reduction 
of dihydrofolate to tetrahydrofolate,11 while SMX is an inhibitor of the dihydropteroate 
synthase (DHPS), the enzyme necessary for the synthesis of folates in fungi.12 The low 
activity of TMP against DHFR is augmented by SMX, in the treatment regimen. The 
efficacy, low cost and activity against a variety of infections has propelled co-trimoxazole to 
be used indiscriminately. Due to the rampant use, mutations in the DHPS locus of P. jirovecii 
(the fungal species that causes PCP in humans) encoding DHPS have been documented as 
the cause of TMP/SMX resistant strains of PCP.12–14 Various studies have also reported 
mutations discovered in pjDHFR after treatment or prophylaxis using DHFR inhibitors.15–19 
Treatment failure and discontinuation of co-trimoxazole occurs in several cases due to such 
resistant strains or toxicity/allergy caused by SMX.20–24 When treatment fails with TMP/
SMX, the second-line treatment in mild to moderate PCP is TMP-dapsone or clindamycin-
primaquine, which also leads to low efficacy and often lethal side-effects.9, 25–27 Piritrexim 
(PTX) and trimetrexate (TMQ) are potent, but non-selective inhibitors of pjDHFR, which 
cause dose-limiting toxicities and have been discontinued.9, 28, 29 For patients that do not 
respond to first line treatment as well the inevitable appearance of resistance, new drugs for 
the treatment of PCP are critically needed.
One of the most efficient strategies to treat PCP infection is to target P. jirovecii DHFR 
(pjDHFR).30 DHFR catalyzes the reduction of 7,8-dihydrofolate to the 5,6,7,8-
tetrahydrofolate. Inhibition of DHFR interferes with folate cofactor requiring 
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transformations including thymidylate and purine biosynthesis and resuls in inhibition of 
DNA synthesis.11 This inhibition causes a disruption in DNA, RNA and protein synthesis of 
the organism and eventually leads to death of the fungus. Pneumocystis infection is host 
specific. Pneumocystis carinii, however, is a distinct species that infects rats, different from 
P. jirovecii, responsible for human infections. The amino acid sequence of the DHFR of 
Pneumocystis carinii (pcDHFR) differs by 38% when compared to the DHFR of 
Pneumocystis jirovecii (pjDHFR).31 Hence, drug’s activity against the surrogate pcDHFR 
in-vitro may not translate into activity in the treatment of PCP infection in humans caused 
by P. jirovecii.
We have recently isolated pjDHFR31 and used it to evaluate clinically used agents such as 
TMP, PTX and novel DHFR inhibitors.32 These studies demonstrated that the inhibition of 
human(h)DHFR compared with pjDHFR allows the calculation of a selectivity ratio (IC50 
hDHFR/IC50 pjDHFR) that provides a measure of the selective inhibition of the agent for 
pjDHFR over hDHFR. Compounds, such as PTX and TMQ, though highly potent, show 
poor selectivity for pjDHFR over hDHFR and are much too toxic in vivo; this lack of 
selectivity is responsible for their discontinuation for the treatment of infections caused by P. 
jirovecii. The selectivity of TMP however, for pjDHFR over hDHFR is 266-fold and 
contributes to its clinical success in PCP treatment. Besides the selectivity for pjDHFR 
another aspect that is highly desirable in an agent is potency for pjDHFR. TMP has a low 
potency as an inhibitor of pjDHFR and must be used with SMX for clinical efficacy. Our 
long-term goal is to provide analogs with excellent potency along with high selectivity for 
pjDHFR. Such agents could be used alone as well as with sulfonamides and other drugs for 
PCP infections in humans.
Rational design of pjDHFR inhibitors is hampered due to a lack of crystal structure 
information for pjDHFR. However, homology models can be used with refinement to model 
pjDHFR in the absence of crystal structures.32 Thus along with known hDHFR X-ray crystal 
structures,33 pjDHFR homology models can be used to design and predict potent and 
selective pjDHFR inhibitors. Another significant impediment in the drug discovery of 
inhibitors of pjDHFR is the inability to grow the organism outside the human lung and 
hence to develop a tissue culture for in vitro studies or an animal model for in vivo 
evaluation of the synthesized compounds. Due to this drawback, isolation and use of 
pjDHFR enzyme is currently the only direct indicator that a compound could be effective (or 
ineffective) in the treatment of PCP infection in humans.
3. Synthesis
Synthesis of 1–18 utilized a modification of the literature method.34 To a solution of 
hydroxyacetone 19 and malononitrile in ethanol, triethylamine was added and stirred 
overnight under argon to afford 20 (Scheme 1). The cyclisation of 20 without purification 
was carried out with guanidine and sodium methoxide at reflux to obtain 21 (10–35%). To a 
solution of iodine and the appropriate thiophenol (2:1 ethanol: water), 21 was added and 
maintained at reflux to afford 1 and 7–12. The pyrrole nitrogen on 1 and 7–12 was 
methylated using sodium hydride and methyl iodide in DMF to afford 2 and 13–18. For the 
N7-alkylated series, 1 was alkylated using appropriate alkyl halides to afford 3–6 (Scheme 
Shah et al. Page 3
Bioorg Med Chem. Author manuscript; available in PMC 2019 May 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2). Synthesis and characterization of compounds 1, 7, 8, and 10 has been presented 
previously by Gangjee et al.34
2. Design and docking studies
We published the X-ray crystal structure of hDHFR and pcDHFR with several pyrido[2,3-
d]pyrimidines.33 In addition, using the published crystal structures for pcDHFR,33 a 
homology model of pjDHFR32 was refined to include the cofactor, nicotinamide adenine 
dinucleotide phosphate (NADPH). This refined pjDHFR homology model was utilized to 
evaluate the docking of the proposed compounds 1–18. The isolation of pjDHFR along with 
the development of the homology model for pjDHFR provided insight regarding the amino-
acid sequence differences between active site of pjDHFR and pcDHFR, as well as that of 
hDHFR. The superimposition of the active site of pcDHFR and pjDHFR (Figure 2) displays 
the amino acid differences present in the active sites of the two enzymes. The active sites of 
pcDHFR has Glu32, Ile33, Ile65, and Phe69, which can affect the binding of the ligands 
designed. The active site of pjDHFR at the same positions in the active site has Asp32, 
Met33, Leu65, and Ser69. These amino acids differ in their size and electrostatics and thus 
would significantly influence the binding of the designed compounds considerably. These 
amino acid differences highlight the futility of designing and evaluating activity against the 
surrogate pcDHFR as inhibitors of pjDHFR.
Gangjee et al.35 reportd 6-substituted pyrrolo[2,3-d]pyrimidines as inhibitors of pcDHFR. 
Reevaluation of compound 1 (Table 1) from this previous study35 in pjDHFR and hDHFR 
enzymes, indicated a moderate inhibitory potency for pjDHFR and marginal selectivity for 
pjDHFR over hDHFR. The reevaluation of 1 in isolated pjDHFR provided a lead analog for 
optimization of both potency and selectivity. We recognized that 1 was overall not as 
selective or potent as TMP; however, it was an improvement in its selectivity over PTX for 
pjDHFR and a good starting structure for improvement in both potency and selectivity.
In order to determine the amino acid differences in the active site of pjDHFR and hDHFR, 
the pjDHFR homology model sequence was superimposed on the hDHFR X-ray crystal 
published with a pyrido[2,3-d]pyrimidine ligand (Figure 3).32, 33 The active site of hDHFR 
is partially composed of Glu30, Phe31, Asn64, and Val115. Analogous to these, the active 
site of pjDHFR is partially composed of the corresponding amino acids Asp32, Met33, 
Ser69, and Ile123. The side chains of these amino acids are different in shape, size and 
electronic properties, which allows the design of inhibitors with selectivity and potency for 
pjDHFR over hDHFR.
Following the evaluation of 1 in pjDHFR and hDHFR, we conducted docking studies of 1 in 
the pjDHFR homology model and in the hDHFR crystal structure (PDB: 4QJC, 1.62 Å)33 
using the molecular modeling program LeadIt 2.1.636 and the parameters specified in the 
Experimental Section. Multiple low energy conformations were obtained on docking 1 in the 
active site of hDHFR and pjDHFR. As a representative example, Figure 4a shows the best 
docked conformation of 1 in the pjDHFR homology model. It displays a bi-dentate ionic 
bond between protonated N1 and 2-NH2 of 1 with Asp32. This interaction is most 
commonly observed in ligands in DHFR crystal structures.37 The 4-NH2 moiety of 1 forms 
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hydrogen bonds with the backbones of Ile10 and the pyrrolo[2,3-d]pyrimidine scaffold is 
stabilized by pi-stacking interaction with Phe36. The 3′-methoxyphenyl moiety of 1 is 
oriented in the pocket formed by Leu 25 (not displayed), Met33, Ser64 and Leu65. The 3′-
methoxyphenyl oxygen forms a hydrogen bonding interaction with Ser64 in the pocket. This 
docked pose generated a docking score of −34 kJ/mol. Figure 4b displays the best docked 
conformation of 1 in hDHFR crystal structure (PDB: 4QJC, 1.61 Å)33. It also exhibits a bi-
dentate ionic interaction of the protonated N1 and 2-NH2 with Glu30. The 4-NH2 displayed 
a hydrogen bonding interaction of with the backbone of Val8 and Val15. The 3′-
methoxyphenyl moiety is oriented in the pocket formed by Leu22 (not displayed), Phe31 
and Ser59. The scaffold is similarly stabilized by pi-stacking interactions with Phe34. This 
docked pose generated a docking score of −29 kJ/mol in the hDHFR crystal structure. The 
docking score comparison between pjDHFR and hDHFR shows a difference of 
approximately 4 kJ/mol, suggesting selectivity of compound 1 for pjDHFR over hDHFR. 
This gain in selectivity could be a consequence of the steric clash of the side chain phenyl 
ring of 1 with Phe31 (in hDHFR) which is absent with Met33 (in pjDHFR). The N7-H of 1 
presents itself towards a hydrophobic pocket formed by Phe31 in hDHFR and Met33 in 
pjDHFR (Figure 4a). We reason that this amino acid variation of Phe31 (in hDHFR) and 
Met33 (in pjDHFR) in the active sites can be further exploited to obtain selectivity for 
pjDHFR. Met33 is comparatively more flexible than Phe31 and hence can better 
accommodate larger inhibitors compared to Phe31. Thus appropriate substitutions on the N7 
of the pyrrolo[2,3-d]pyrimidine scaffold of 1 could target this amino acid difference. The 
predicted distances of the N7 in 1 is approximately 4.89 Å from Met33 in the pjDHFR 
docked pose and approximately 3.57 Å from Phe31 in the hDHFR docked pose. Thus, a 
methyl substitution on N7 of 1 could create favorable hydrophobic interactions with Met33 
in the pjDHFR active site and an unfavorable steric clash with the Phe31 in the hDHFR 
active site. To further validate our hypothesis, the N7-methyl analog of 1, 2 was also docked, 
synthesized, and evaluated.
The introduction of the N7-methyl moiety affords two significant changes in the molecule. 
First, it increases the hydrophobic interactions in both pjDHFR and hDHFR active sites. The 
second change is the decrease in the number of low energy conformations possible for 2 
within 1 kcal/mol, compared to 1. This is a direct consequence of the further restricted 
rotation of the 6-aryl moiety due to the presence of the 5,7-dimethyl groups. The number of 
conformations possible for 1 and 2 were calculated using Sybyl38 and were found to be 122 
and 72, respectively. Thus, conformational restriction induced by the N7-methyl group could 
afford the bioactive conformation or, at least, easier access to the bioactive conformation of 
2 in pjDHFR. These two attributes resulting from the addition of the N7-methyl group could 
be responsible for an increase in potency of 2 over 1. The docking studies of 2 in the 
pjDHFR homology model and the hDHFR crystal structure (PDB: 4QJC, 1.62 Å);33 
displays the interactions as expected (Figure 5a and 5b). The N7-methyl group is indeed 
oriented towards the hydrophobic pocket in both pjDHFR and hDHFR active sites. The 
docking scores of 2 in the pjDHFR homology model and the hDHFR crystal structure were 
−36 kJ/mol and −25 kJ/mol respectively. The difference in the docked scores between 
pjDHFR and hDHFR, of 11 kJ/mol also predicts an increased selectivity for pjDHFR.
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Evaluation of 2 in enzyme assays displayed increased potency towards pjDHFR and a 8-fold 
selectivity in inhibition of pjDHFR over hDHFR (Table 2). Compared to the activity of 1, 
the increase in potency towards pjDHFR can be attributed, in part, to the hydrophobic 
binding of the N7-methyl group in the pocket formed by Met33 and Leu25 (not displayed) 
and the easier access to the bound conformation, whereas the selectivity increase could be 
due to a probable steric clash between the N7-methyl group of 2 with Phe31 in hDHFR thus 
making the binding of 2 less favorable in hDHFR than 1. These evaluations (in vitro IC50) 
validate our homology model and docking methods. Owing to a large size of the pocket, the 
N7-methyl did not create a substantial increase in potency and/or selectivity, as expected. 
Hence it was of interest to synthesize and evaluate longer chain N7-substituetnts of 2, Series 
1 (Table 2, compounds 3–6). These longer alkyl chains at the N7 exhibited an increased 
potency for pjDHFR, but 4 afforded a selectivity of 24-fold for pjDHFR over hDHFR, which 
was the highest observed for the pyrrolo[2,3-d]pyrimidine series. To structurally explain 
these results, we performed docking of 4 in the pjDHFR homology model (Figure 6a) and 
the hDHFR crystal structure (Figure 6b). In the homology model of pjDHFR, the terminus 
of the propyl chain was at a distance of 3.54 Å from Met33, in pjDHFR. This pose showed 
an excellent docking score of −36 kJ/mol, and the compound displayed an inhibitory 
potency IC50 of 74 nM for pjDHFR. The modelling of 4 in hDHFR showed the docked pose 
as depicted in Figure 6b and the docked score obtained was −24 kJ/mol. The low docking 
score suggested a less than appropriate fit of 4 in active site of hDHFR. The low score 
observed, also, reinforces the possibility of a steric clash of the propyl moiety with Phe31 
(as observed in Figure 6c), which explains a decreased potency of 4 in the hDHFR. On 
homologation to a N7-n-butyl and branching to i-propyl, the activity and selectivity against 
pjDHFR does not increase significantly, indicating that the propyl chain is optimal at N7-
position for this series.
Our efforts at targeting the hydrophobic pocket containing Met33 (in pjDHFR) and Phe31 
(in hDHFR) led to 4. It was of interest to study the effect of other amino acid differences 
within the active site where the side chain aryl group binds. The amino acids at a distance of 
4.5 Å around the ligand were studied (Figure 6). The pocket in pjDHFR is composed of 
Met33, Ser64 and Leu65 and Ile123 and Asp21, Phe31, Ser59 and Val115 in hDHFR. Thus, 
the active sites have different electronics, shape and size which could affect the binding 
properties of the pocket. To achieve potency and selectivity by targeting these differing 
residues, the side-chain aryl substituents with electron withdrawing, electron donating and 
sterically bulky groups, as replacements for the 3′-methoxyphenyl group were attempted 
(Table 3, Compounds 7–12). Evaluation of 7–12 led to potent and selective compounds 9 
and 12 (Table 3). The 2-napthyl and 4-trifluromethoxyphenyl substitutions showed a 2-fold 
increase in potency and a 2-fold increase in selectivity, compared to 1. The gain in potencies 
of 9 and 12 in pjDHFR, compared to 1, could be due to productive shape complementarity 
of the side chain aryl group and the pocket formed by Met33, Ser64 and Leu65. The gain in 
selectivity of 9 and 12 for pjDHFR over hDHFR, compared to 2, could be due to the steric 
clash of the bulkier side chain aryl moiety with Phe31 (in hDHFR), which is absent with 
Met33 (in pjDHFR). The high probability of a steric hindrance between the bulky side chain 
aryl group in these compounds with Phe31 in hDHFR is evident in the docking studies of 9 
in the crystal structure of hDHFR (PDB: 4QJC, 1.62 Å)33 in Figure 7. The Phe31 in the 
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hDHFR active site limits the movement of the side chain and forces a steric hindrance which 
decreases the potency of the larger side chain aryl groups, for hDHFR.
Since N7-methylation of 1 afforded an increase in potency and selectivity, we methylated the 
N7-position of 7–12 to afford 13–18 (Table 4). The N7-methlyation with varied side chain 
aryl group did not afford an increase in potency or selectivity and 4 remained the most 
selective compound in this series.
4. X-ray Crystal Structures (PDB Accession Numbers hDHFR-3 (5HT4); hDHFR-14 
(5HT5) for compounds 3 and 14)
Structural data were measured for the ternary complexes of NADPH and native human 
DHFR with inhibitors 3 (Table 2) and 14 (Table 4), respectively, to validate the binding 
interactions of these inhibitors in the active site of hDHFR (Figure 8). Compound 3 was 
selected for its high selectivity and potency in pjDHFR. These data reveal that the presence 
of the N7-ethyl group of 3 causes the conformation of Phe31 to differ from that observed in 
the hDHFR complex with 14; Phe31 adopts alternate positions with partial occupancy. It is 
also interesting to note that the small shift in the binding orientation of inhibitors 3 and 14 
allows the 3′-methoxy and the 4′-methoxy of 3 and 14 respectively to occupy similar 
positions in the binding site.
The overall structures of hDHFR in complex with 3 and 14 are similar to those reported for 
other hDHFR inhibitor complexes.19, 32, 33 As observed in Figure 8, for 3 and 14, the 3′-
methoxy and the 4′-methoxy substituents occupy the same binding pocket. In 3, the amino 
group of the side chain of Asn64 is within hydrogen bonding distance to the 3′-methoxy 
oxygen (2.9 Å) and the 4′-methoxy oxygen is within 3.4 Å of the Asn64 amino moiety in 
14. The interactions of the N7-methyl substituent of 3 and N7-ethyl substituent of 14 results 
in Phe31 having two alternate conformations. Analysis of the intermolecular interactions 
involving the C5-methyl substituent of 3 and 14 shows hydrophobic contacts (4.3 and 4.6 Å, 
respectively) with the C5 of Val115. The 4-NH2 group of the inhibitors 3 and 14 form a 
hydrogen bond with the backbone carbonyl of Val115 (3.0 and 3.3 Å, respectively). Docking 
studies of 3 and 14 in the hDHFR crystal structure (PDB ID: 4QJC)33 afforded poses which 
mimic the conformation obtained from the crystal structures of hDHFR as a ternary complex 
with 3 and 14 (Figure 8). This further validates our docking protocols.
5. Summary
The X-ray crystal structures of 3 and 14 in hDHFR validate our hypothesis that bulk at the 
N7-position of the pyrrolo[2,3-d]pyrimidine scaffold results in a steric clash with Phe31. We 
have successfully designed, synthesized and evaluated novel series of analogs to explore 
active site amino acid residue differences in hDHFR and pjDHFR enzymes in our attempt to 
afford selective inhibitors of pjDHFR over hDHFR. This effort led to several compounds (3–
6 and 12) exhibiting potency greater than TMP (92 nM) and selectivity greater than PTX 
(0.05-fold). The docking studies and crystal structures reveal the importance of targeting the 
differences in amino acid residues in the active site of pjDHFR and hDHFR. These 
predictions from the docking studies and the X-ray crystal studies were corroborated by the 
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biological evaluation results. Compound 4 afforded the best selectivity for pjDHFR over 
hDHFR (24 fold) with a potency of 84 nM for pjDHFR. This suggested that the optimum 
bulk at the N7-position of the pyrrolo[3,2-d]pyrimidine scaffold, that can be tolerated for 
increased binding to pjDHFR active site and causing steric clash with hDHFR active site, is 
equivalent to a propyl group. Compound 4 maintained the potency equivalent to PTX, but 
exhibited a 48-fold increase in selectivity for pjDHFR over hDHFR. Utilizing the 
information provided in this study has allowed the design and synthesis of potentially more 
potent and selective compounds that are currently underway and will be the subject of future 
publications.
6. Experimental Section
6.1 Synthesis
All evaporations were carried out in vacuo with a rotary evaporator. Analytical samples were 
dried in vacuo (0.2 mm Hg) in a CHEM-DRY drying apparatus over P2O5 at 70 °C. Melting 
points were determined on a MEL-TEMP II melting point apparatus with FLUKE 51 K/J 
electronic thermometer and are uncorrected. Nuclear magnetic resonance spectra for proton 
(1H NMR) was recorded on a Bruker 400/500 MHz NMR spectrometer. The chemical shift 
values are expressed in ppm (parts per million) relative to tetramethylsilane as an internal 
standard: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad singlet. The 
relative integrals of peak areas agreed with those expected for the assigned structures. High-
resolution mass spectra (HRMS) were recorded on a MICROMASS AUTOSPEC (EBE 
Geometry) double focusing mass spectrometer (Electron Impact – EI) or Waters Q-TOF 
(quadrupole/time-of-flight tandem instrument) mass spectrometer (Electro-Spray Ionization 
– ESI). Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, GA. 
Element compositions are within 0.4% of the calculated values. Fractional moles of water or 
organic solvents frequently found in some analytical samples of antifolates could not be 
prevented in spite of 24–48 h of drying in vacuo and were confirmed where possible by their 
presence in the 1H NMR spectra. Thin-layer chromatography (TLC) was performed on 
WHATMAN UV254 silica gel plates with a fluorescent indicator, and the spots were 
visualized under 254 and/or 365 nm illumination. Proportions of solvents used for TLC are 
by volume. Column chromatography was performed on a 230–400 mesh silica gel purchased 
from Fisher Scientific. All solvents and chemicals were purchased from Sigma-Aldrich 
Chemical Co. or Fisher Scientific.
Procedure for the Synthesis of Compounds 1, 7–12
2-Amino-4-methyl-furan-3-carbonitrile (20): To a solution of acetol (10 g, 135 mmol) in 
methanol (200mL) at room temperature was added malononitrile (8.9 g, 135 mmol) and 
triethylamine (13.7 g, 135 mmol). The resulting mixture was stirred at room temperature 
overnight. The reaction mixture was then stripped of solvent in vacuo. The residue was 
washed with hexane-ethyl acetate (5:1) (250mL × 5). The resulting hexane-ethyl acetate 
solution of the product was collected. After the evaporation of solvent under reduced 
pressure, 13 g (79%) of the crude product was obtained as an orange powder and was used 
directly in the next reaction without analysis.
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2,4-Diamino-5-methyl-pyrrolo[2,3-d]pyrimidine (21): To a solution of guanidine free base 
(from 82 mmol of NaOMe) in anhydrous ethanol (150 mL) was added aminonitrile 20 (10.0 
g, 82 mmol). The mixture was refluxed for 24 h, cooled, and filtered. The filtrate was 
evaporated in vacuo, and the residue was chromatographed on silica gel with 10% MeOH/
CHCl3 as the eluent. Fractions containing the product were combined and evaporated to give 
24 (7.3g, 55%) as a light brown solid; TLC Rf 0.63 (MeOH/ CHCl3/NH4OH, 1:5:0.5); mp, 
166–168 °C. 1H NMR (400 Hz) (Me2SO-d6) δ 2.23 (s, 3 H, 5-CH3), 5.25–5.78 (br, 2 H, 2-
NH2, exch.), 6.19 (s, 2 H, 4-NH2, exch.), 6.42 (s, 1 H, 6-H), 10.43 (s, 1 H, 7-H, exch.).
5-methyl-6-(naphthalen-2-ylthio)thieno[2,3-d]pyrimidine-2,4-diamine (9): Compound 9 
(0.32 g, 21%) was obtained from 21 (0.8 g, 4.4 mmol), 2-thionapthalene (1.42 g, 8.8 mmol), 
and iodine (2.25 g, 8.8 mmol); TLC Rf 0.50 (MeOH/CHCl3/NH4OH, 1:5:0.5); mp, 191.8–
193.5°C. 1H NMR (400 Hz) (Me2SO-d6) δ 2.09 (s, 3H, 5-CH3), 5.66 (s, 2 H, 2-NH2, exch.), 
6.32 (s, 2 H, 4-NH2, exch.), 7.17 (dd, 1H, C6H4, J=1.8Hz, J=8.7Hz), 7.45 (m, 3H, C6H4), 
7.76 (d, 1H, J=8.3Hz), 7.82 (s, 1H, C6H4), 7.84 (m, 1H, C6H4), 11.05 (s, 1 H, 7-H, exch.). 
Anal. Calcd. for C17H15N5S: C, 63.53; H, 4.70; N, 21.79; S, 9.98. Found: C, 62.22; H, 4.86; 
N, 20.99; S, 9.60.
6-((3,4-difluorophenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine 
(11): Compound 11 (0.35 g, 24.3%) was obtained from 21 (0.8 g, 4.4 mmol), 3,4-
difluorothiophenol (1.30 g, 8.8 mmol), and iodine (2.25 g, 8.8 mmol); TLC Rf 0.50 (MeOH/
CHCl3/NH4OH, 1:5:0.5); mp, 291.7–295.8 °C. 1H NMR (500 Hz) (Me2SO-d6) δ 2.33 (s, 
3H, 5-CH3), 5.65 (s, 2 H, 2-NH2, exch.), 6.28 (s, 2 H, 4-NH2, exch.), 6.81 (d, 1 H, C6H4, 
J=8.7Hz), 7.06 (d, 1 H, C6H4, J=19.2Hz), 7.37 (dd, 1 H, C6H4, J=8.6Hz, J=19.2Hz), 10.99 
(s, 1 H, 7-H, exch.). Anal. Calcd. for C13H11F2N4S 0.34 CH3OH: C, 50.87; H, 4.05; F, 
11.76; N, 21.68; S, 9.93. Found: C, 50.97; H, 3.88; F, 11.55; N, 21.65; S, 10.06.
6-((4-trifluromethoxyphenyl)thio)-5-methylthieno[2,3-d]pyrimidine-2,4-diamine 
(12): Compound 12 (0.38 g, 28%) was obtained from 21 (0.8 g, 4.4 mmol), 4-
trifluromethoxythiophenol (1.26 g, 8.8 mmol), and iodine (2.25 g, 8.8 mmol); TLC Rf 0.50 
(MeOH/CHCl3/NH4OH, 1:5:0.5); mp, 291.7–295.8 °C. 1H NMR (500 Hz) (Me2SO-d6) δ 
2.33 (s, 3 H, 5-CH3), 5.66 (s, 2 H, 2-NH2, exch.), 6.28 (s, 2 H, 4-NH2, exch.), 7.08 (d, 2 H, 
C6H4, J=8.9 Hz), 7.30 (d, 2 H, C6H4, J= 8.1 Hz), 10.98 (s, 1 H, 7-H, exch.). Anal. Calcd. for 
C14H12F3N5OS: C, 47.32; H, 3.40; F, 16.04; N, 19.71; O, 4.50; S, 9.02. Found: C, 47.13; H, 
3.50; F, 15.99; N, 19.57; S, 8.91
General Procedure for the Synthesis of Compounds 2–6, 13–18—Mixture of 6-
substituted pyrrolo[2,3-d]pyrimidine and sodium hydride was added to a three neck RBF. 
The RBF was made anhydrous using argon gas balloon. To this mixture, anhydrous DMF 
(10 mL) was added and stirred for 30 minutes with vigorous stirring. Subsequently, 
appropriate alkyl halide was injected in the reaction mixture, and the resulting reaction 
mixture was stirred and monitored by TLC until reaction was completed. The DMF was 
evaporated under vacuum and silica plug was prepared. The final compound was purified by 
flash chromatography using methanol-chloroform gradient elution.
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6-((3-methoxyphenyl)thio)-5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(2): Reaction of 1 (0.150 g, 0.32 mmol), sodium hydride (0.012g, 0.5 mmol) and 
iodomethane (31 mmL, 0.5 mmol) using the general procedure described above gave 2 
(0.120 g, 76.44%) as white solid; TLC Rf 0.58 (MeOH/CHCl3/NH4OH, 1:5:0.5); mp, 
277.4–279.4 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 2.38 (s, 3 H, 5-CH3), 3.37 (s, 3 H, 7-
CH3), 3.69 (s, 3 H, 3-OCH3), 5.81 (s, 1.68 H, 2-NH2, exch.), 6.37 (s, 1.58 H, 4-NH2, exch.), 
6.49 (dd, 2 H, C6H4, J=1.76, 10.55 Hz), 6.73 (dd, 1 H, C6H4, J=2.35, 8.20 Hz), 7.19 (t, 1 H, 
C6H4, J=7.96, 7.96 Hz). HRMS (ESI) calculated for C15H17N5OS [M+H]+, 316.12266. 
Found: 316.12198. Found: 316.12198. HPLC analysis: retention time, 22.79 min; peak area, 
96.08%; eluent A, H2O: eluent B, ACN; gradient elution (100% H2O to 10% H2O) over 60 
min with flow rate of 0.5 mL/min and detection at 245 nm; column temperature, rt
7-ethyl-6-((3-methoxyphenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(3): Reaction of 1 (0.150 g, 0.50 mmol), sodium hydride (0.012g, 0.5 mmol) and 
bromoethane (53 mmL, 0.5 mmol) using the general procedure described above gave 3 
(0.095 g, 60.5%) as white solid; TLC Rf 0.58 (MeOH/CHCl3/NH4OH, 1:5:0.5); mp, 136.9–
139.4 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 1.04 (t, 3 H, J = 7.0 Hz, -CH3), 2.37 (s, 3 H, 5-
CH3), 3.68 (s, 3 H, 3-OCH3), 3.92 (q, 2 H, J = 7.0 Hz, -CH2-), 5.80 (s, 2 H, 2-NH2, exch.), 
6.35 (s, 2 H, 4-NH2, exch.), 6.49 (d, 2 H, J = 7.2 Hz, C6H4), 6.72 (dd, 1 H, C6H4, J = 2.1 Hz, 
J = 7.2 Hz), 7.19 (t, 1 H, C6H4, J = 8.2 Hz). Anal. Calcd. for C16H19N5OS: C, 58.34; H, 
5.81; N, 21.26; O, 4.86; S, 9.73. Found: C, 58.0.; H, 5.97; N, 21.05; S, 9.52
6-((3-methoxyphenyl)thio)-5-methyl-7-propyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (4): Reaction of 1 (0.120 g, 0.50 mmol), sodium hydride (0.012g, 0.5 mmol) and 1-
bromopropane (62 mmL, 0.5 mmol) using the general procedure described above gave 4 
(0.050 g, 37%) as white solid; TLC Rf 0.60 (MeOH/CHCl3/NH4OH, 1:5:0.5); mp, 266.4–
268.2 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 0.73 (t, 3H, J=7.4Hz, -CH3), 1.51 (qd, 2H, 
J=7.2Hz, J=14.5Hz, -CH2-), 2.37 (s, 3 H, 5-CH3), 3.35 (s, 3 H, 3-OCH3), 3.83 (t, 2H, 
J=14.5Hz, -CH2-), 3.92 (q, 2 H, J = 7.0 Hz, -CH2-), 5.79 (s, 2 H, 2-NH2, exch.), 6.35 (s, 2 H, 
4-NH2, exch.), 6.49 (d, 2 H, J = 7.2 Hz, C6H4), 6.72 (dd, 1 H, C6H4, J = 2.1 Hz, J =7.2 Hz), 
7.19 (t, 1 H, C6H4, J = 8.2 Hz).). Anal. Calcd. for C17H21N5OS: C, 59.45; H, 6.16; N, 20.39; 
O, 4.66; S, 9.34. Found: C, 58.72; H, 6.23; N, 19.97; S, 8.98.
7-isopropyl-6-((3-methoxyphenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (5): Reaction of 1 (0.090 g, 0.30 mmol), sodium hydride (0.009g, 0.36 mmol) and 
2-romopropane (38 mmL, 0.36 mmol) using the general procedure described above gave 5 
(0.060 g, 59%) as white solid; TLC Rf 0.60 (MeOH/CHCl3/NH4OH, 1:5:0.5); mp, 157.4–
160.1 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 1.40 (d, 6H, J=6.7 Hz, -CH3), 2.38 (s, 3 H, 5-
CH3), 3.68 (s, 3 H, 3-OCH3), 4.13(m, 1 H, -CH-), 5.80 (s, 2 H, 2-NH2, exch.), 6.49 (s, 2 H, 
4-NH2, exch.), 6.49 (d, 2 H, J = 7.2 Hz, C6H4), 6.72 (dd, 1 H, C6H4, J = 2.1 Hz, J = 7.2 Hz), 
7.19 (t, 1 H, C6H4, J = 8.2 Hz). Anal. Calcd. for C17H21N5OS: C, 59.45; H, 6.16; N, 20.39; 
O, 4.66; S, 9.34. Found: C, 59.12; H, 6.08; N, 19.65; S, 8.87
7-butyl-6-((3-methoxyphenyl)thio)-5-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(6): Reaction of 1 (0.100 g, 0.33 mmol), sodium hydride (0.010g, 0.4 mmol) and 1-
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bromobutane (55 mmL, 0.5 mmol) using the general procedure described above gave 6 
(0.065 g, 55%) as white solid; TLC Rf 0.62 (MeOH/CHCl3/NH4OH, 1:5:0.5); mp, 282.4–
284.2 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 0.76 (t, 3H, J=7.3Hz, -CH3), 1.14 (qd, 2H, 
J=7.2Hz, J=14.6Hz, -CH2-), 1.45 (td, 2 H, J=7.5Hz, J=14.7Hz, -CH2-), 2.38 (s, 3 H, 5-CH3), 
3.68 (s, 3 H, 3-OCH3), 3.87 (t, 2 H, J=14.5Hz, -CH2-),3.92 (q, 2 H, J = 7.0 Hz, -CH2-), 5.80 
(s, 2 H, 2-NH2, exch.), 6.49 (s, 2 H, 4-NH2, exch.), 6.49 (d, 2 H, J = 7.2 Hz, C6H4), 6.72 (dd, 
1 H, C6H4, J = 2.1 Hz, J = 7.2 Hz), 7.19 (t, 1 H, C6H4, J = 8.2 Hz). Anal. Calcd. for 
C18H23N5OS 0.03 CHCl3: C, 59.98; H, 6.43; N, 19.40; O, 4.48; S, 8.88. Found: C, 59.94; H, 
6.25; N, 19.38; S, 8.78.
6-((2-methoxyphenyl)thio)-5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(13): Reaction of 7 (0.150 g, 0.5 mmol), sodium hydride (0.012g, 0.5 mmol) and 
iodomethane (31 mmL, 0.5 mmol using the general procedure described above gave 13 (0.1 
g, 64%) as a white solid; TLC Rf 0.58 (MeOH/CHCl3/NH4OH, 1:5:0.5); mp, 208.6–
209.6 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 2.34 (s, 3 H, 5-CH3), 3.37 (s, 3 H, 7-CH3), 3.89 
(s, 3 H, 2-OCH3), 5.76 (s, 2 H, 2-NH2, exch.), 6.35 (s, 2 H, 4-NH2, exch.), 6.81 (m, 2 H, 
C6H4), 7.01 (d, 1 H, J=6.7 Hz, C6H4), 7.11 (d, 1 H, J=7.8 Hz, C6H4). HRMS (ESI) 
calculated for C15H17N5OS [M+H]+, 316.12266. Found: 316.12402. HPLC analysis: 
retention time, 21.99 min; peak area, 97.37 %; eluent A, H2O: eluent B, ACN; gradient 
elution (100% H2O to 10% H2O) over 60 min with flow rate of 0.5 mL/min and detection at 
245 nm; column temperature, rt.
6-((4-methoxyphenyl)thio)-5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(14): Reaction of 8 (0.150 g, 0.32 mmol), sodium hydride (0.012g, 0.5 mmol) and 
iodomethane (31 mmL, 0.5 mmol) using the general procedure described above gave 14 
(0.135 g, 86%) as white solid; TLC Rf 0.58 (MeOH/CHCl3/NH4OH, 1:5:0.5); mp, 266.0–
267.8 °C; 1H NMR (400 Hz) (Me2SO-d6) δ 2.38 (s, 3 H, 5-CH3), 3.37 (s, 3 H, 7-CH3), 3.69 
(s, 3 H, 3-OCH3), 5.81 (s, 2 H, 2-NH2), 6.37 (s, 2 H, 4-NH2), 6.49 (dd, J=1.76, 10.55 Hz, 2 
H, C6H4), 6.73 (dd, J=2.35, 8.20 Hz, 1 H, C6H4), 7.19 (t, J=7.96, 7.96 Hz, 1 H, C6H4). Anal. 
Calcd. for C15H17N5OS: C, 57.12; H, 5.43; N, 22.21; O, 5.07; S, 10.17. Found: C, 56.90; H, 
5.48; N, 21.94; S, 10.01.
5,7-dimethyl-6-(naphthalen-2-ylthio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(15): Reaction of 9 (0.18 g, 0.56 mmol), sodium hydride (0.016g, 0.67 mmol) and 
iodomethane (40 mmL, 0.64 mmol) using the general procedure described above gave 15 
(0.11 g, 59%) as white solid; TLC Rf 0.57 (MeOH/CHCl3/NH4OH, 1:5:0.5);); mp, 266.0–
267.8 °C 1H NMR (400 Hz) (Me2SO-d6) δ 2.43 (s, 3 H, 5-CH3), 3.40 (s, 3H, 7-CH3), 5.82 
(s, 2 H, 2-NH2, exch.), 6.39 (s, 2 H, 4-NH2, exch.), 7.13 (d, 1H, J=8.7Hz), 7.45 (dd, 3 H, 
J=6.7Hz, J=12.8Hz)), 7.78 (d, 1 H, J=7.8Hz), 7.85 (d, 2 H, J=8.6Hz). Anal. Calcd. for 
C18H17N5S: C, 64.45; H, 5.11; N, 20.88; S, 9.56. Found: C, 64.21; H, 5.25; N, 20.68; S, 
9.29
5,7-dimethyl-6-(naphthalen-1-ylthio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(16): Reaction of 10 (0.20 g, 0.62 mmol), sodium hydride (0.017g, 0.75 mmol) and 
iodomethane (46 mmL, 0.72 mmol) using the general procedure described above gave 16 
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(0.12 g, 57%) as white solid; TLC Rf 0.57 (MeOH/CHCl3/NH4OH 1:5:0.5); mp, 232.6–
235.6 °C 1H NMR (400 Hz) (Me2SO-d6) δ 2.51 (s, 3H, 5-CH3), 3.39 (s, 3H, 7-CH3), 5.89 
(s, 2 H, 2-NH2, exch.), 6.49 (s, 2 H, 4-NH2, exch.), 6.64 (d, 1 H, C6H4, J=7.3 Hz), 7.34 (t, 1 
H, J= 7.8 Hz), 7.63 (td, 2 H, J=6.9Hz, J=14.9Hz,), 7.72 (d, 1 H, J=8.1Hz), 7.96 (d, 1 H, 
J=8.0Hz), 8.28 (d, 1 H, J=8.3Hz). Anal. Calcd. for C18H17N5S: C, 64.45; H, 5.11; N, 20.88; 
S, 9.56. Found: C, 64.68; H, 4.91; N, 20.82; S, 9.59
6-((3,4-difluorophenyl)thio)-5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
(17): Reaction of 11 (0.120 g, 0.39 mmol), sodium hydride (0.012g, 0.5 mmol) and 
iodomethane (31 mmL, 0.5 mmol) using the general procedure described above gave 17 
(0.08 g, 64%) as white solid; TLC Rf 0.57 (MeOH/CHCl3/NH4OH, 1:5:0.5); mp, 266.0–
267.8 °C 1H NMR (500 Hz) (Me2SO-d6) δ 2.38 (s, 3 H, 5-CH3), 3.34 (s, 3 H, 7-CH3), 5.83 
(s, 2 H, 2-NH2, exch.), 6.38 (s, 2 H, 4-NH2, exch.), 6.75 (d, 1 H, C6H4, J=8.7Hz), 7.06 (ddd, 
1 H, C6H4, J=2.3Hz, J=7.4Hz, J=10.8Hz), 7.37 (ddd, 1 H, C6H4, J=2.3Hz, J=7.4Hz, 
J=10.8Hz). Anal. Calcd. for C14H13F2N5S 0.04 CHCl3: C, 51.71; H, 4.03; F, 11.65; N, 
21.47; S, 9.64. Found: C, 51.75; H, 4.01; F, 11.47; N, 21.30; S, 9.74
5,7-dimethyl-6-((4-(trifluoromethoxy)phenyl)thio)-7H-pyrrolo[2,3-d]pyrimidine-2,4-
diamine (18): Reaction of 12 (0.150 g, 0.42 mmol), sodium hydride (0.012g, 0.5 mmol) and 
iodomethane (32 mmL, 0.5 mmol) using the general procedure described above gave 18 (0.1 
g, 48%) as white solid; TLC Rf 0.57 (MeOH/CHCl3/NH4OH, 1:5:0.5); mp, 282.0–283.8 °C 
1H NMR (400 Hz) (Me2SO-d6) δ 2.39 (s, 3 H, 5-CH3), 3.38 (s, 3 H, 7-CH3), 5.88 (s, 2 H, 2-
NH2, exch.), 6.47 (s, 2 H, 4-NH2, exch.), 7.06 (d, 2 H, C6H4, J=8.2 Hz), 7.29 (d, 2 H, C6H4, 
J= 8.3 Hz). Anal. Calcd. for C15H14F3N5OS: C, 48.78; H, 3.82; F, 15.43; N, 18.96; O, 4.33; 
S, 8.68. Found: C, 49.03; H, 4.01; F, 18.93; N, 18.93; S, 8.61
6.2 Molecular Modeling
Docking of compounds 1–18 was carried out using the published X-ray crystal structure of 
N6-methyl-N6-(3,4,5-trifluorophenyl)pyrido[3,2-d]pyrimidine-2,4,6-triamine in 
hDHFR(PDB: 4QJC, 1.62 Å)33 and in the homology model of pjDHFR32 using LeadIT 
2.1.636. The docking in LeadIT was constrained to the active site of the protein. Polar 
hydrogen atoms of amino acids were not constrained, thereby permitting them free rotation. 
Base placement of fragments for docking was carried out using triangle docking. Default 
parameters were used for scoring and clash handling. The maximum number of solutions per 
iteration and maximum number of fragmentation were set to 200. Ten poses were obtained 
per molecule. The docked poses were exported to MOE 2016.08 for visualization.39 The 
validation of LeadIT as a suitable docking system for pjDHFR and hDHFR was carried out 
by re-docking the native ligands in the x-ray crystal structures of pcDHFR (PDB: 2FZI)40 
and hDHFR (PDB: 4QJC). The ligands were sketched in MOE 2016.0839 and docking was 
carried out with LeadIT 2.1.6 as described above. The best docked pose of the ligands had 
RMSD of 0.7060 Å in pjDHFR and 0.8860 Å in hDHFR. Thus, LeadIT 2.1.6 was validated 
and chosen for the docking studies.
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6.3 Pharmacological assay
The expression and purification of recombinant pj- and hDHFR was carried out as 
previously described.18 Standard DHFR assays were conducted at 37°C with continuous 
recording of change of absorbance at 340 nM. The assay contained 41 mM sodium 
phosphate buffer at pH 7.4, 8.9 mM 2-mercaptoethanol, 150 mM KCl, and saturating 
concentrations of NADPH (117 μM). Dihydro folic acid (DHFA) was used at an optimum 
concentration of 9 μM. The results reported previously by Namjoshi et al.31 were carried out 
at 18 M of DHFA.
6.4 Crystallization and X-ray Data Collection and Refinement
Expression and purification of wild type human dihydrofolate reductase (hDHFR) were 
carried out as previously described.41 Recombinant hDHFR was washed in a Centricon-10 
with 100 mM K2HPO4 buffer pH 6.9 with 30% saturated ammonium sulfate and 
concentrated to 7.9 mg ml−1. The hDHFR samples were incubated for 1 h on ice with a 
tenfold excess of NADPH and compounds 3 and 14, respectively, prior to crystallization 
using the hanging-drop vapor diffusion method using siliconized glass cover slips and 
storage at 14°C. Protein droplets of the hDHFR complexes contained K2HPO4 pH 6.9 with 
30% saturated ammonium sulfate equilibrated against a reservoir solution consisting of 100 
mM K2HPO4 pH 6.9 with 60% saturated ammonium sulfate, 3% (v/v) ethanol. Crystals of 
hDHFR-3-NADPH and hDHFR-14-NADPH ternary complex were hexagonal and belonged 
to the space group H3. Data were collected at 100K to 1.46Å resolution for both crystals 
using the remote access robot on beamline 14.7 at the Stanford Synchrotron Radiation 
Laboratory.19, 42–44 The data were processed using HKL2000 program package.45 The 
diffraction statistics are shown in Table 5. Both crystal structures were solved by molecular 
replacement methods using the coordinates for hDHFR (1u72)46 in the program Molref.47 
Inspection of the resulting difference electron density maps made using COOT48 running on 
an iMac workstation revealed density for the ternary complex of both crystals. The final 
cycles of refinement were carried out using the program Refmac5 in the CCP4 suite of 
programs.47 The Ramachandran conformational parameters from the last cycle of refinement 
generated by RAMPAGE49 showed that more than 96% of the residues refined have the 
most favored conformation and none are in the disallowed regions. Coordinates for these 
structures have been deposited with the Protein Data Bank.
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Pj Pneumocystis jirovecii
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PCP Pneumocystis pneumonia
ART antiretroviral therapy
TMP trimethoprim
SMX sulfamethoxazole
DHFR dihydrofolate reductase
DHPS dihydropteroate synthase
PTX Piritrexim
TMQ trimetrexate
PC Pneumocystis carinii
References
1. Kovacs, JA. 349 - Pneumocystis Pneumonia A2 - Goldman, Lee. In: Schafer, AI., editor. Goldman’s 
Cecil Medicine (Twenty-Fourth Edition). W.B. Saunders; Philadelphia: 2012. p. 1997-2005.
2. Huang YS, Yang JJ, Lee NY, Chen GJ, Ko WC, Sun HY, Hung CC. Treatment of Pneumocystis 
jirovecii pneumonia in HIV-infected patients: a review. Expert Rev Anti Infect Ther. 2017; 15:873–
892. [PubMed: 28782390] 
3. Sokulska M, Kicia M, Wesołowska M, Hendrich AB. Pneumocystis jirovecii—from a commensal to 
pathogen: clinical and diagnostic review. Parasitol Res. 2015; 114:3577–3585. [PubMed: 26281787] 
4. Yiannakis EP, Boswell TC. Systematic review of outbreaks of Pneumocystis jirovecii pneumonia: 
evidence that P. jirovecii is a transmissible organism and the implications for healthcare infection 
control. The Journal of hospital infection. 2016; 93:1–8. [PubMed: 26996089] 
5. Goldman, L., Schafer, AI. Goldman-Cecil Medicine. Elsevier Health Sciences; 2015. 
6. Bernheimer JM, Patten G, Makeleni T, Mantangana N, Dumile N, Goemaere E, Cox V. Paediatric 
HIV treatment failure: a silent epidemic. J Intl AIDS Soc. 2015; 18:20090.
7. Armstrong-James D, Meintjes G, Brown GD. A neglected epidemic: fungal infections in HIV/
AIDS. Trends in microbiology. 2014; 22:120–7. [PubMed: 24530175] 
8. Harris JR, Balajee SA, Park BJ. Pneumocystis Jirovecii Pneumonia: Current Knowledge and 
Outstanding Public Health Issues. Curr Fungal Infect Rep. 2010; 4:229–237.
9. Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE. Prevention and treatment of 
opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the 
Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine 
Association of the Infectious Diseases Society of America. Clinical infectious diseases: an official 
publication of the Infectious Diseases Society of America. 2014; 58:1308–11. [PubMed: 24585567] 
10. Miller RF, Huang L, Walzer PD. Pneumocystis Pneumonia Associated with Human 
Immunodeficiency Virus. Clin Chest Med. 2013; 34:229–241. [PubMed: 23702173] 
11. Hawser S, Lociuro S, Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem 
Pharmacol. 2006; 71:941–8. [PubMed: 16359642] 
12. Yoon C, Subramanian A, Chi A, Crothers K, Meshnick SR, Taylor SM, Beard CB, Jarlsberg LG, 
Lawrence GG, Avery M, Swartzman A, Fong S, Roth B, Huang L. Dihydropteroate Synthase 
Mutations in Pneumocystis Pneumonia: Impact of Applying Different Definitions of Prophylaxis, 
Mortality Endpoints and Mutant in a Single Cohort. Med Mycol. 2013; 51:568–575. [PubMed: 
23470037] 
13. Huang L, Crothers K, Atzori C, Benfield T, Miller R, Rabodonirina M, Helweg-Larsen J. 
Dihydropteroate Synthase Gene Mutations in Pneumocystis and Sulfa Resistance. Emerg Infect 
Dis. 2004; 10:1721–1728. [PubMed: 15504256] 
Shah et al. Page 14
Bioorg Med Chem. Author manuscript; available in PMC 2019 May 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
14. Ponce CA, Chabe M, George C, Cardenas A, Duran L, Guerrero J, Bustamante R, Matos O, Huang 
L, Miller RF, Vargas SL. High Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase 
Gene Mutations in Patients with a First Episode of Pneumocystis Pneumonia in Santiago, Chile, 
and Clinical Response to Trimethoprim-Sulfamethoxazole Therapy. Antimicrob Agents 
Chemother. 2017; 61:e01290–16. [PubMed: 27855071] 
15. Queener SF, Cody V, Pace J, Torkelson P, Gangjee A. Trimethoprim resistance of dihydrofolate 
reductase variants from clinical isolates of Pneumocystis jirovecii. Antimicrob Agents Chemother. 
2013; 57:4990–8. [PubMed: 23896474] 
16. Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM. Mutations of Pneumocystis 
jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents 
Chemother. 2004; 48:4301–5. [PubMed: 15504856] 
17. Siripattanapipong S, Leelayoova S, Mungthin M, Worapong J, Tan-Ariya P. Study of DHPS and 
DHFR genes of Pneumocystis jirovecii in Thai HIV-infected patients. Med Mycol. 2008; 46:389–
392. [PubMed: 18415849] 
18. Cody V, Pace J, Queener SF, Adair OO, Gangjee A. Kinetic and Structural Analysis for Potent 
Antifolate Inhibition of Pneumocystis jirovecii, Pneumocystis carinii, and Human Dihydrofolate 
Reductases and Their Active-Site Variants. Antimicrob Agents Chemother. 2013; 57:2669–2677. 
[PubMed: 23545530] 
19. Cody V, Pace J, Makin J, Piraino J, Queener SF, Rosowsky A. Correlations of Inhibitor Kinetics 
for Pneumocystis jirovecii and Human Dihydrofolate Reductase with Structural Data for Human 
Active Site Mutant Enzyme Complexes. Biochemistry. 2009; 48:1702–1711. [PubMed: 19196009] 
20. Yang JJ, Huang CH, Liu CE, Tang HJ, Yang CJ, Lee YC, Lee KY, Tsai MS, Lin SW, Chen YH, Lu 
PL, Hung CC. Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: 
incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii 
pneumonia. PloS one. 2014; 9:e106141. [PubMed: 25184238] 
21. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in 
patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984; 100:495–499. 
[PubMed: 6230976] 
22. Masters PA, O’Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim-sulfamethoxazole revisited. 
Arch Intern Med. 2003; 163:402–410. [PubMed: 12588198] 
23. Floris-Moore MA, Amodio-Groton MI, Catalano MT. Adverse Reactions to Trimethoprim/
Sulfamethoxazole in AIDS. Ann Pharmacother. 2003; 37:1810–1813. [PubMed: 14632594] 
24. Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ: 
Canadian Medical Association journal = journal de l’Association medicale canadienne. 2011; 
183:1851–8.
25. Sangiolo D, Storer B, Nash R, Corey L, Davis C, Flowers M, Hackman RC, Boeckh M. Toxicity 
and Efficacy of Daily Dapsone as Pneumocystis jiroveci Prophylaxis after Hematopoietic Stem 
Cell Transplantation: A Case-Control Study. Biol Blood Marrow Transplant. 2005; 11:521–529. 
[PubMed: 15983552] 
26. White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007; 7:549–558. [PubMed: 
17646028] 
27. Nickel P, Schurmann M, Albrecht H, Schindler R, Budde K, Westhoff T, Millward J, Suttorp N, 
Reinke P, Schurmann D. Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal 
transplant patients. Infection. 2014; 42:981–9. [PubMed: 25168263] 
28. Kovacs JA, Allegra CJ, Swan JC, Drake JC, Parrillo JE, Chabner BA, Masur H. Potent 
antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. Antimicrob 
Agents Chemother. 1988; 32:430–433. [PubMed: 2967669] 
29. Short CES, Gilleece YC, Fisher MJ, Churchill DR. Trimetrexate and folinic acid: a valuable 
salvage option for Pneumocystis jirovecii pneumonia. AIDS. 2009; 23:1287–1290. [PubMed: 
19424049] 
30. Gangjee A, Kurup S, Namjoshi O. Dihydrofolate reductase as a target for chemotherapy in 
parasites. Curr Pharm Des. 2007; 13:609–39. [PubMed: 17346178] 
Shah et al. Page 15
Bioorg Med Chem. Author manuscript; available in PMC 2019 May 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
31. Cody V, Chisum K, Pope C, Queener SF. Purification and characterization of human-derived 
Pneumocystis jirovecii dihydrofolate reductase expressed in Sf21 insect cells and in Escherichia 
coli. Protein Expr Purif. 2005; 40:417–23. [PubMed: 15766885] 
32. Gangjee A, Namjoshi OA, Raghavan S, Queener SF, Kisliuk RL, Cody V. Design, synthesis, and 
molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of 
Buchwald-Hartwig aminations of heterocycles. J Med Chem. 2013; 56:4422–41. [PubMed: 
23627352] 
33. Cody V, Pace J, Namjoshi OA, Gangjee A. Structure-activity correlations for three pyrido[2,3-
d]pyrimidine antifolates binding to human and Pneumocystis carinii dihydrofolate reductase. Acta 
Crystallogr F Struct Biol Commun. 2015; 71:799–803. [PubMed: 26057816] 
34. Taylor EC, Patel HH, Jun JG. A One-Step Ring Transformation/Ring Annulation Approach to 
Pyrrolo[2,3-d]pyrimidines. A New Synthesis of the Potent Dihydrofolate Reductase Inhibitor 
TNP-351. J Org Chem. 1995; 60:6684–6687.
35. Gangjee A, Lin X, Queener SF. Design, synthesis, and biological evaluation of 2,4-diamino-5-
methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors. Journal of 
medicinal chemistry. 2004; 47:3689–92. [PubMed: 15214795] 
36. LeadIT 2.1.6. Biosolve IT; St. Augustin, Germany: www.biosolveit.de
37. Cody V, Schwalbe CH. Structural characteristics of antifolate dihydrofolate reductase enzyme 
interactions. Crystallography Reviews. 2006; 12:301–333.
38. SYBYL-X 2.1.1. Tripos International; 1699 South Hanley Rd. St. Louis, Missouri, 63144; USA: 
39. Molecular Operating Environment (MOE), 2016.08. Chemical Computing Group ULC; 1010 
Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7: 2017. 
40. Cody V, Pace J, Chisum K, Rosowsky A. New insights into DHFR interactions: analysis of 
Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(omega-
carboxy(alkyloxy) trimethoprim derivatives reveals conformational correlations with activity and 
novel parallel ring stacking interactions. Proteins. 2006; 65:959–69. [PubMed: 17019704] 
41. Cody V, Pace J, Makin J, Piraino J, Queener SF, Rosowsky A. Correlations of inhibitor kinetics for 
Pneumocystis jirovecii and human dihydrofolate reductase with structural data for human active 
site mutant enzyme complexes. Biochemistry. 2009; 48:1702–11. [PubMed: 19196009] 
42. Cohen AE, Ellis PJ, Miller MD, Deacon AM, Phizackerley RP. An automated system to mount 
cryo-cooled protein crystals on a synchrotron beam line, using compact sample cassettes and a 
small-scale robot. J Appl Crystallogr. 2002; 35:720–726. [PubMed: 24899734] 
43. González AMP, McPhillips S, Song J, Sharp K, Taylor J, Adams P, Sauter N, Soltis S. Web-Ice: 
integrated data collection and analysis for macromolecular crystallography. J Appl Crystallogr. 
2008; 41:176–184.
44. McPhillips TM, McPhillips SE, Chiu HJ, Cohen AE, Deacon AM, Ellis PJ, Garman E, Gonzalez 
A, Sauter NK, Phizackerley RP, Soltis SM, Kuhn P. Blu-Ice and the Distributed Control System: 
software for data acquisition and instrument control at macromolecular crystallography beamlines. 
Journal of synchrotron radiation. 2002; 9:401–6. [PubMed: 12409628] 
45. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. 
Methods Enzymol. 1997; 276:307–26.
46. Cody V, Luft JR, Pangborn W. Understanding the role of Leu22 variants in methotrexate 
resistance: comparison of wild-type and Leu22Arg variant mouse and human dihydrofolate 
reductase ternary crystal complexes with methotrexate and NADPH. Acta Crystallogr D Biol 
Crystallogr. 2005; 61:147–55. [PubMed: 15681865] 
47. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, 
Leslie AGW, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton EA, Powell HR, 
Read RJ, Vagin A, Wilson KS. Overview of the CCP4 suite and current developments. Acta 
Crystallogr D Biol Crystallogr. 2011; 67:235–242. [PubMed: 21460441] 
48. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr 
D Biol Crystallogr. 2010; 66:486–501. [PubMed: 20383002] 
49. Lovell SC, Davis IW, Arendall WB 3rd, de Bakker PI, Word JM, Prisant MG, Richardson JS, 
Richardson DC. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins. 
2003; 50:437–50. [PubMed: 12557186] 
Shah et al. Page 16
Bioorg Med Chem. Author manuscript; available in PMC 2019 May 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
DHFR inhibitors for treatment for PCP
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Figure 2. 
Superimposition of active sites of pcDHFR and pjDHFR. The blue ribbon and amino acid 
residues represent the active site of pcDHFR (PDB: 4QJZ, 1.61 Å).33 The pink ribbon and 
amino acid residues represent the homology model of pjDHFR active site. The ligand N6-
methyl-N6-(naphthalen-2-yl)pyrido[2,3-d]pyrimidine-2,4,6-triamine (magenta) was co-
crystallized with hDHFR.33
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Figure 3. 
Superimposition of active sites of hDHFR and pjDHFR. The amino acid residues shown are 
the residues that are different in the active site of the two species. The grey ribbon and amino 
acid residues co-crystallized with the ligand, N6-methyl-N6-(3,4,5-
trifluorophenyl)pyrido[2,3-d]pyrimidine-2,4,6-triamine (magenta), represent the active site 
of hDHFR (PDB: 4QJC, 1.62 Å).33 The pink ribbon and amino acid residues represent the 
homology model of pjDHFR active site.
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Figure 4. 
Docked pose of 1 (cyan) in (a) homology model of pjDHFR and (b) crystal structure of 
hDHFR (PDB: 4QJC, 1.62 Å)33.
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Figure 5. 
Docked pose of 2 (cyan) in (a) homology model of pjDHFR and (b) crystal structure of 
hDHFR (PDB: 4QJC, 1.62 Å)33
Shah et al. Page 21
Bioorg Med Chem. Author manuscript; available in PMC 2019 May 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. 
(a) Docked pose of 4 (cyan) in the homology model of pjDHFR; (b) docked pose of 4 (cyan) 
in the crystal structure of hDHFR (PDB: 4QJC, 1.62 Å)33 and (c) space-filled representation 
of Phe31 residue and N7-propyl group in the docked pose of 4 (cyan) in the crystal structure 
of hDHFR (PDB: 4QJC, 1.62 Å)33 to illustrate the high probability of steric clash.
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Figure 7. 
Docked pose of 9 (cyan) in the crystal structure of hDHFR (PDB ID: 4QJC)33. The Phe 31 
residue is shown in a space fill view to illustrate the high probability of steric clash with the 
side chain aryl group of 9.
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Figure 8. 
(a) Comparison of the crystal structures of human DHFR as a ternary complex with 3 
(yellow) and 14 (green) showing the electron density for the complex with hDHFR-3 (2Fo-
Fc, 1σ, blue, 3σ, green) and (b) Comparison of the binding pocket for hDHFR-3 (yellow) 
and 14 (green). Note that Phe31 occupies two alternative conformations in these two 
structures. This change is in response to the larger N7-ethyl substituent of the inhibitor 3 as 
compared to N7-methyl substituent of 14.
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Scheme 1. 
a) malononitrile, TEA, EtOH, rt, 12h; b) NaOMe, guanidine HCl, EtOH, reflux, 24h; c) 
thiophenol, I2, 2:EtOH:H2O, reflux, 24h; d) CH3I, NaH, DMF, rt, 0.5– 2h
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Scheme 2. 
a) R-Br, NaH, DMF, rt, 0.5– 2h
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Table 1
Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity Ratios
# pjDHFR (nM) hDHFR (nM) Selectivity Ratio [hDHFR/pjDHFR]
1 213 970 5
TMP 92 24500 266
PTX 41 2 0.05
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Table 2
Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity Ratios
# R pjDHFR (nM) hDHFR (nM) Selectivity Ratio [hDHFR/pjDHFR]
1 H 213 970 5
2 CH3 160 1200 8
3 CH2CH3 35 511 15
4 CH2CH2CH3 84 2046 24
5 CH(CH3)2 74 579 8
6 CH2CH2CH2CH3 73 1130 15
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Table 3
Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity Ratios
# R pjDHFR (nM) hDHFR (nM) Selectivity Ratio [hDHFR/pjDHFR]
1 3′-OCH3Ph 213 970 5
7 2′-OCH3Ph 177 624 4
8 4′-OCH3Ph 252 1410 6
9 2-Naph 101 2100 12
10 1-Naph 167 1216 7
11 3′,4′-diFPh 240 2318 10
12 4′-OCF3Ph 81 811 10
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Table 4
Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity Ratios
# R pjDHFR (nM) hDHFR (nM) Selectivity Ratio [hDHFR/pjDHFR]
2 3′-OCH3Ph 160 1200 8
13 2′-OCH3Ph 210 1400 7
14 4′-OCH3Ph 219 1372 6
15 2-Naph 130 970 7
16 1-Naph 177 1104 6
17 3′,4′-diFPh 247 1917 8
18 4′-OCF3Ph 110 1101 10
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Table 5
Crystal Properties and Refinement Statistics of 3 and 14 bound to hDHFR
Compound (B2-282) 3 (A6-283) 14
PDB accession 5HT4 5HT5
Space Group H3 H3
Lattice constants (Å)/°
a 85.68 85.45
b 85.68 85.45
c 77.03 77.69
α 90.0 90.0
β 90.0 90.0
γ 120.0 120.0
Beamline SSRL 14-1 SSRL 14-1
Resolution Å 1.46 (1.49) 1.46 (1.49)
Wavelength Å 0.979 0.979
Rmerge %a,b 0.05 (0.067) 0.174 (0.136)
Completeness % 92.6 (46.2) 78.9 (70.6)
Observed Reflect 121,242 49,944
Unique Reflections 37,327 36,629
I/σ(I) 35.0 (0.90) 34.5 (2.4)
Multiplicitya 2.0 (1.4) 1.3 (1.2)
Reflections used 25,428 12,777
Resolution Å 34.2 – 1.60 26.3 – 1.90
R-factor 0.24 0.19
Rfree 0.30 0.28
Total protein atoms 1677 1653
Total water atoms 78 75
Average B-factor Å2 28.2 33.2
Error in Luzzati plot 0.27 0.24
Rms deviation from ideal
Bond length Å 0.021 0.021
Bond angle 2.38 2.23
Ramachandran plot
Most favored % 96.7 95.7
Additional allowed % 2.7 3.3
Disallowed % 0.5 1.1
a
The values in parentheses refer to data in the highest resolution shell.
b
Rsym = ΣhΣi|Ih,i − <Ih>| / ΣhΣi|Ih,i|, where <Ih> is the mean intensity of a set of equivalent reflections.
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c
R-factor = Σ|Fobs − Fcalc| / ΣFobs, where Fobs and Fcalc are observed and calculated structure factor amplitudes.
d
Rfree-factor was calculated for R-factor for a random 5% subset of all reflections.
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